Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.  The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Preliminary results of the study were presented yesterday by lead investigator, Jeffrey E. Lancet, M.D. of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida at the 55th American Society of Hematology Annual Meeting and Exhibition (ASH), held this week in New Orleans, Louisiana.

"We are encouraged by the results seen with KB004 to date, which has been well-tolerated at doses up to 190 mg, with mild to moderate transient infusion reactions the most common toxicity," said Dr. Lancet. "There are some signs of activity as well, including a patient with relapsed acute myeloid leukemia (AML) who had sustained remission for over 1 year."

Escalating doses of KB004 were administered as a 1 or 2 hour infusion on days 1, 8, and 15 of a 21 day cycle at incremental doses of 20, 40, 70, 100, 140, 190 and 250 mg and will thereafter increase at 33% increments up to a planned maximum of 700 mg. The primary study objective is to determine a maximum tolerated dose, which has not yet been reached. Secondary objectives included evaluation of pharmacokinetics, imm
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2015)... TOWN, South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and ... with the "2015 African Biometrics Company of the Year ... in Nigeria .   -Cross ... and http://www.presseportal.de/nr/8896 - On Thursday evening, ...
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... and sugary foods. Or do they? New research contradicts the ... the same taste in food and highlights the importance of ... SINC Until now the scientific community ... drinks, the very foods that are the most damaging to ...
... The association between road traffic and heart disease has been ... study from Denmark showed that traffic noise was significantly associated ... increase in noise exposure (either at the time of the ... a 12% increased risk.(1) Now, a new study presented ...
... fish, with an intriguing past, now has had its ... genetic changes that accompanied the adaptation from an aquatic ... by Chris Amemiya, PhD, Director of Molecular Genetics at ... Professor of Biology at the University of Washington, will ...
Cached Biology News:Tell me where you're from and I'll tell you what tastes you prefer 2Long-term exposure to fine particles of traffic pollution increases risk of heart disease 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
(Date:9/2/2015)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... presentations at three investor conferences: , Wednesday, September ... in New York at the New ... PM at the BioCentury NewsMakers Conference in New ... Center , Thursday, September 17 at 9:30 AM at ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "DNA ... their offering. This report briefly reviews ... technologies, and their applications. Current large and small ... them. Various applications of sequencing are described including ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... of Sessions, led by the Industry,s Preeminent Thought ... Diagnosis and TreatmentCAMBRIDGE, Mass., March 24 TechConnect ... Technology Institute (NSTI), and the Clean Technology and ... 2009 Symposium, scheduled to take place at TechConnect ...
... dental biomaterials market will rebound to reach upwards of ... Mass., March 24 According to Millennium Research Group,s ... report, although dental biomaterials are being used in a ... these products will be dampened by the global financial ...
... SOUTH SAN FRANCISCO, Calif., March 24 Catalyst ... development of engineered proteases known as Alterase(TM) therapeutics, ... Scientific Advisory Board (SAB). Robert J. Fletterick, ... and Gregory Stahl, Ph.D., join initial members Shaun ...
Cached Biology Technology:TechConnect World Announces The CancerNano 2009 Symposium May 3-7, at the George R. Brown Convention Center in Houston 2TechConnect World Announces The CancerNano 2009 Symposium May 3-7, at the George R. Brown Convention Center in Houston 3TechConnect World Announces The CancerNano 2009 Symposium May 3-7, at the George R. Brown Convention Center in Houston 4How Long Will the Economic Downturn Affect the Dental Biomaterials Market? 2Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 2Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 3Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 4Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 5Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 6
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Molecular Probes intensely fluorescent and highly ... for use in a variety of ... a strong signal. Unfortunately, protein- and ... that may cause them to bind ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Source: Tritirachium album Description: ... endopeptidase used in a wide range of applications ... peptide bonds mainly following the carboxyl group of ... and is classified as a serine protease. ...
Biology Products: